{"disease":{"id":"oral-premalignant-lesions","name":"oral premalignant lesions"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04504552","title":"Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","has_results":false},{"nct_id":"NCT06087042","title":"Dipeptidyl Peptidase-4 Link With Oral Cancer and Premalignant Lesions","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Fayoum University","has_results":false},{"nct_id":"NCT04913545","title":"The Senstivity and Specificity of Using Salivary miRNAs in Detection of Malignant Transformation of Oral Lesions.","phase":"","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Cairo University","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}